Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta ... in a single once-daily dose in GSK’s Ellipta dry powder inhaler. Novartis says its results support ...
Median time to remission was 24 weeks and median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to decline above a dose of 40 mg with 26% ...
Subjects were then randomised to receive either an extra inhalation ... single-dose Seretide™ and 8% receiving double-dose Seretide™ had a QTc change from baseline in the interval 30 59 ...
Aims The presence of propellant in the metered dose inhalers (MDI) makes it challenging to identify when the inhaler is empty. Studies have shown that up to 86 actuations can be done just with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback